Effectiveness of low-level laser therapy in lichen planopilaris
To the Editor: Lichen planopilaris (LPP) is a lymphocytic scarring alopecia of unknown origin in which the hair follicle stem cells are destroyed by an autoimmune mechanism. 1, 2 This condition tends to be progressive, and the most effective .012 (Basal [ 6 mo)
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1 Lowlevel laser therapy (LLLT) is an emerging light therapy, with a reported effectiveness in several inflammatory diseases, such as lichen planus, although results are sometimes biased. 3 Our objective was to evaluate the potential usefulness of LLLT in patients with LPP.
A 6-month prospective interventional study was performed including patients with clinically and histologically diagnosed LPP. This research was approved by our Human Research Subjects Committee (227-16). The main clinical variable was the Lichen Planopilaris Activity Index (LPPAI), 2 with a final score of 1-10. Vidix polarized video dermatoscope (Medici Medical, Modena, Italy) was used for mapping 5 specific hair fields located at the same sites (3 frontal and 2 on scarring plaques) during each visit to evaluate trichoscopic images and to assess inflammation ( perifollicular erythema and hyperkeratosis) and terminal and global hair follicle thickness. Both videodermatoscopic mapping and cutaneous marks were used to identify hair fields. Standardized pictures were obtained at each visit.
A total of 8 white patients (5 (Table I) . Ledsmedical devices with high-powered unfocused 246 red LED (Skymedic, Barcelona, Spain), at a wavelength of 630 nm and a fluence of 4 J/cm 2 , were used 15 minutes daily for 6 months.
All patients responded with a global reduction of symptoms, erythema, and perifollicular hyperkeratosis (Fig 1, A and B) , with a mean decrease of 0.87 in LPPAI score after 6 months of intervention (P ¼ .012) but not at the 3-month follow-up visit. Terminal hair thickness after 3 months (111.0 m vs 71.7 m, P ¼ .018) and 6 months (82.4 m vs 71.7 m; P ¼ .035) was greater than that at baseline. Other clinical data is shown in Table I .
Severe cases of LPP might be resistant to classical drugs. 2 This is the first study showing the potential effectiveness of LLLT in scarring alopecias. Interestingly, there are preliminary reports indicating that light therapies (low-dose 308-nm excimer laser) reduce inflammation in LPP patients. 4 Remarkably, a significant decrease in inflammation was observed in our cohort of LPP patients after 6 months of LLLT. A significant hair thickening was also detected, maybe related to its positive effect on the follicular cycle 5 ; however, a narrowing was noted during the last 3 months of therapy, plausibly caused by tachyphylaxis. Recently, a malfunction in peroxisome proliferatoractivator receptor (PPAR-) has been described in LPP, which is leading to new therapies such as PPAR-activators or thiazolidinediones. 6 Interestingly, LLLT has been demonstrated to increase PPAR-expression in murine models of inflammation. 7 The limitations of our study include the small sample size, the lack of a control group, and the absence of histologic data. Conflicts of interest: None disclosed. To the Editor: Diffuse capillary malformation with overgrowth (DCMO) was recently described as a distinct subtype of vascular anomaly characterized by extensive capillary malformations (CMs) involving [1 anatomic region. 1 Most patients exhibit proportionate soft tissue or bony overgrowth that does not correlate with CM location or intensity.
1 Somatic mutations in GNA11 have been identified in DCMO, suggesting that aberrant mitogen-activated protein kinase signaling contributes to pathogenesis. 2 Because little is known about long-term outcomes in DCMO, we conducted a Boston Children's Hospital Institutional Review Boardeapproved anonymous REDCap survey. 3 Sixty-nine patients [5 years of age previously given a DCMO diagnosis and registered in the Vascular Anomalies Center database were contacted.
1 Thirty-one patients or parents of patients (45%) completed questionnaires about the vascular anomaly, overgrowth, and physical and psychological outcomes. Table I summarizes patient demographics. The mean age was 14.2 years. CMs were most commonly located on the posterior trunk and lower extremities, and overgrowth most frequently involved the extremities. Table II summarizes long-term outcomes. Nineteen of 31 (61%) patients, including 12 of the 13 with facial involvement, had laser therapy; 95% of the patients who had laser therapy reported response to treatment. Leg-length discrepancy (LLD) affected 19 of 31 (61%) patients; 63% of these individuals received treatments such as orthotics, surgical interventions, and physical therapy. Although no patient in the original cohort had true varicosities, 1 which would support an alternative diagnosis, 18 of 31 (58%) follow-up patients reported prominent veins or other venous abnormalities, including varicose veins, and 2 were treated with compression stockings or partial venectomy. No patient reported treatment for arm-length discrepancy, macrodactyly, or syndactyly; ability to perform daily tasks was largely unaffected.
We inquired about clinical features associated with other vascular anomalies that manifest over time (Table I) . 1, 4 One patient's diagnosis was subsequently changed to Sturge-Weber syndrome 4 because of the development of glaucoma with a facial CM. Scoliosis affected both sexes equally and did not correlate with LLD (Fisher's exact test, P ¼ .4472), suggesting improper management of LLD was not responsible. No patient reported lipomas, hypotonia, seizures, lower extremity thrombosis, or malignancy. Ten (32%) patients reported psychosocial difficulties, eg, low selfesteem, anxiety, and social discomfort, with no sex predilection. Psychosocial distress most often manifested in early adolescence but was also reported in patients as young as 6 years of age while undergoing laser therapy. Of note, 7 (23%) patients or parents of patients self-reported no overgrowth. Very mild asymmetry can be difficult to ascertain and might have been deemed unreportable, or perhaps soft tissue overgrowth improved with time.
An infant without obvious overgrowth should be given a diffuse capillary malformation diagnosis and evaluated closely for development of overgrowth until adulthood. We found no evidence
